Blue Owl Capital Holdings LP’s portfolio moves, tracked quarter by quarter, based on its SEC Form 13F filings. These filings offer a quarterly snapshot of U.S. equity holdings for institutional investment managers, revealing what a fund added, trimmed, or exited entirely. They do not show exact trade dates or the reasoning behind a move, but tracked over time they help paint a picture of where a manager’s conviction is building or fading. This page is updated each quarter as new filings become available, so bookmark it if you follow this fund’s activity.
Notable moves during the quarter ending 2026-03-31
The largest change this quarter was a full exit from BlackRock Inc common stock, a position previously worth over $1 billion, making it by far the most significant portfolio adjustment in the filing. On the buy side, Blue Owl opened a new position in Aktis Oncology (AKTS) worth roughly $56.6 million, its biggest new addition of the quarter. Smaller new positions were also opened in Corvus Pharmaceuticals (CRVS), Rhythm Pharmaceuticals (RYTM), and Ovid Therapeutics (OVID).
Among existing holdings, Maplight Therapeutics (MPLT) saw the sharpest increase, up 256% to roughly $20.5 million, while Eyepoint (EYPT) rose 64% and Larimar Therapeutics (LRMR) grew 23%. On the reduction side, Sagimet Biosciences (SGMT) was cut by 76%, Dell Technologies (DELL) by 66%, and Civeo Corp by 44%. Smaller trims touched Holley Inc (HLLY), Compass Therapeutics (CMPX), and Blue Owl Capital Corporation (OWL) itself, the latter down 13% to about $22.6 million.
Several other positions were exited entirely, including Repare Therapeutics, Roivant Sciences (ROIV), Immuneering (IMRX), Payoneer Global (PAYO), Centessa Pharmaceuticals, and Compass Pathways (CMPS). Together with the BlackRock exit, this marks a quarter with a notable amount of portfolio turnover, particularly within smaller biotech and clinical-stage names.
What this tells us about positioning
Taken together, the filing shows continued activity in early-stage biotech and pharmaceutical names alongside a large reduction in broad market exposure through the BlackRock exit. New positions in AKTS, CRVS, RYTM, and OVID suggest ongoing interest in the sector, even as several other biotech holdings were trimmed or closed out. As with any single quarter of 13F data, this is a snapshot rather than a complete picture of intent, and future filings will show whether these newer positions are built upon or unwound. Check back next quarter for the latest update to this profile, which will track how these holdings evolve.
Related ticker coverage
- AKTS — all coverage →
- MPLT — all coverage →
- CRVS — all coverage →
- LRMR — all coverage →
- SGMT — all coverage →
- ROIV — all coverage →
- RYTM — all coverage →
- EYPT — all coverage →
- OVID — all coverage →
- DELL — all coverage →
- HLLY — all coverage →
- IMRX — all coverage →
- PAYO — all coverage →
- CMPX — all coverage →
- OWL — all coverage →
- CMPS — all coverage →
Source: SEC Form 13F filings. This page updates every quarter.